B1344

DRUG2 trials

Sponsors

Tasly Biopharmaceuticals Co., Ltd.

Conditions

NAFLD (Non-alcoholic Fatty Liver Disease)NASH (Nonalcoholic Steatohepatitis)Nonalcoholic Steatohepatitis

Phase 1

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Tasly Biopharmaceuticals Co., Ltd.Nonalcoholic Steatohepatitis

Start: 2022-08-30End: 2024-01-30Target: 56Updated: 2022-12-19

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

RecruitingNCT07128797

Tasly Biopharmaceuticals Co., Ltd.NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)

Start: 2025-07-24End: 2026-07-31Target: 32Updated: 2025-08-19